Tara Sanft Discusses Advancements in HER2+ Treatments

Video

Tara Sanft, MD, of Smilow Cancer Hospital at Yale-New Haven Hospital describes some of the new treatments for patients with HER2+ breast cancer.

Among the drugs available, Sanft explains that pertuzumab used along with trastuzumab and chemotherapy, produces a better chance that the patient will have a pathologic complete response (pCR). Patients who reach pCR go on to have a better prognosis.

Recent Videos
a woman sitting in front of a green wall with a white top and glasses
a woman with a white shirt and glasses sitting in front of a green wall.
Related Content
Amanda Brink, DNP, APRN, FNP-BC, AOCNP

Opinion: A Case of Self-Experimentation with Oncolytic Virus Therapy Highlights the Need for More Research

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
December 30th 2024
Article

Oncology nurses can educate patients about the potential indications for oncolytic virus therapy and connect them to available clinical trial opportunities.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

breast cancer

Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes

Darlene Dobkowski, MA
December 23rd 2024
Article

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Lindsay Fischer
January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

circulating tumor DNA

Study Supports Role of ctDNA in Predicting Outcomes in HR+ Early Breast Cancer

Ashley Chan
December 17th 2024
Article

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

breast cancer

Addition of Perioperative Atezolizumab Does Not Improve EFS in TNBC

Jason Broderick
December 16th 2024
Article

Perioperative atezolizumab did not improve outcomes in patients with triple-negative breast cancer.